Merck’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value. Merck ...

In the closing of the recent trading day, Merck (MRK) stood at $117.23, denoting a -1.19% change from the preceding trading day.

The stock's fall snapped a five-day winning streak.

Merck (MRK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

The FDA has approved Merck's Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for first-line ...

Deep-pocketed investors have adopted a bullish approach towards Merck & Co MRK, and it's something market players shouldn't ...

Drug major Merck & Co., Inc. (MRK) announced Wednesday that the U.S. Food and Drug Administration has approved its anti-PD-1 therapy ...

Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a ...

Merck (NYSE:MRK) announced Wednesday that the U.S. Food and Drug Administration (FDA) approved a label expansion for its ...

Merck & Co Inc (MRK) stock saw a modest uptick, ending the day at $117.96 which represents a slight increase of $2.10 or 1.81% from the prior close of $115.86. The stock opened at $115.8 and touched a ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...